<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Dec. 20, 2019 (HealthDay News) — For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast cancer (SBC), according to a study published in the November issue of the Journal of the National Comprehensive Cancer Network<\/i>.<\/p>\n
Using the Surveillance, Epidemiology, and End Results database, Puyao C. Li, M.D., from Brigham and Women’s Hospital in Boston, and colleagues identified 3,407 patients who received breast-conserving therapy with or without RT for primary DCIS in 2000 through 2013 and subsequently developed a stage I to III invasive SBC.<\/p>\n
The researchers found that even after controlling for cancer stage, prior RT was associated with higher rates of breast cancer-specific mortality (hazard ratio, 1.70; 95 percent confidence interval, 1.18 to 2.45; P = 0.005). The risk trended higher in patients with ipsilateral versus contralateral SBC (hazard ratio, 2.07 versus 1.26; P = 0.16). Patients with ipsilateral SBC were younger and more often lacked estrogen receptor expression compared with patients who developed contralateral SBC.<\/p>\n
“These findings may have implications for treatment decision-making in DCIS and after development of SBC, and highlight the value of a careful discussion with patients before treatment,” the authors write.<\/p>\n